GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer
Giving cisplatin during pelvic radiotherapy nearly halved the risk of death compared with radiotherapy with hydroxyurea in locally advanced cervical cancer, establishing weekly cisplatin chemoradiation as the worldwide standard.
Overview
Phase 3 trial of 526 women with stage IIB to IVA cervical cancer randomised to radiotherapy with weekly cisplatin, with cisplatin plus fluorouracil and hydroxyurea, or with hydroxyurea alone.
Both cisplatin arms improved progression-free and overall survival compared with hydroxyurea (relative risk of death 0.61 and 0.58), and weekly cisplatin was the least toxic, becoming the standard regimen.
- Relative risk of death 0.61 with weekly cisplatin vs hydroxyurea.
- Four-year progression-free survival about 65 percent with cisplatin vs 47 percent with hydroxyurea.
Weekly cisplatin with external beam radiotherapy and brachytherapy remains the backbone of curative treatment for locally advanced cervical cancer; INTERLACE and KEYNOTE-A18 build on it.
- The comparator (hydroxyurea) is not a no-chemotherapy control.
- Brachytherapy technique has since advanced.
Similar pages
not linked directly; found by shared links- TrialCALLA
- TrialA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- TrialA Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the
- Key paperABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer
Shares New England Journal of Medicine, Cisplatin.
- Key paperTreatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide
Shares New England Journal of Medicine, Cisplatin.
- TrialINTERLACE
- TrialKEYNOTE-A18 / ENGOT-cx11 / GOG-3047